Researchers from the University of Colorado School of Medicine have reported a breakthrough discovery of a process to expand production of stem cells used to treat cancer patients. These findings could have implications that extend beyond cancer, including treatments for inborn immunodeficiency and metabolic conditions and autoimmune diseases.
In an article published online on August, 29, 2014 in PLOS ONE, researchers from the Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology, located at the University of Colorado’s Anschutz Medical Campus and Taiga Biotechnologies, Inc., based in, Aurora, Colorado, said they have uncovered the keys to the molecular code that appear to regulate the ability of blood stem cells to reproduce and retain their stem-like characteristics.
The team developed protein products that can be directly administered to blood stem cells to encourage them to multiply without permanent genetic modifications.
The ability to multiply blood stem cells from any source in a dish will be critical for adoption of this new technology in clinics…
Adequate Supplies
“Use of stem cells to treat cancer patients who face bone marrow transplants has been a common practice for four decades,” said Yosef Refaeli, Ph.D., an associate dermatology professor and one of the study’s lead scientists. “The biggest challenge, however, has been finding adequate supplies of stem cells that help patients fight infection after the procedure.”
Gates Stem Cell Center Director Dennis Roop, Ph.D., recognized the magnitude of the team’s work. “Researchers have long attempted to increase the number of blood stem cells in a lab,” Roop noted. “Most of those approaches have been limited by the nature of the resulting cells or the inadequate number of cells produced.”
White blood cells
The technology described in the PLOS ONE article has worked with blood stem cells obtained from cord blood, adult bone marrow or peripheral blood from adults.
“The ability to multiply blood stem cells from any source in a dish will be critical for adoption of this new technology in clinics,” said Brian Turner, Ph.D., MHS, Taiga Biotechnologies’ chief scientific officer. Turner is also one of the paper’s lead authors.
From lab to clinical trials
The goal now is to move the technology from the lab into clinical trials. Taiga Biotechnologies is in the process of setting up first-in-human clinical trials with the blood stem cell expansion approaches described in the article.
The clinical applications for expanded human blood stem cells vary from inborn immunodeficiency conditions, like SCID and sickle cell anemia, to metabolic conditions, like Hurler’s disease or Gaucher syndrome. Autoimmune diseases that could be affected include severe multiple sclerosis and lupus. And the types of cancer that could be treated as a result of this research include leukemia, lymphoma, myeloma and other types of solid tumors.
For more information
Bird GA, Polsky A, Estes P, Hanlon T, Hamilton H, Morton JJ, Gutman J, Jimeno A, Turner BC, Refaeli Y. Expansion of Human and Murine Hematopoietic Stem and Progenitor Cells Ex Vivo without Genetic Modification Using MYC and Bcl-2 Fusion Proteins. PLoS ONE 9(8): e105525. doi:10.1371/journal.pone.0105525 [Article]
Copyright ? 2014 Sunvalley Communication. All rights reserved. Republication or redistribution of Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of Sunvalley Communication. Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.
